XellSmart
company
About
Xellsmart develops stem cell treatment solutions for a variety of degenerative diseases for which there are now no clinical treatments.
- Minhang,Shanghai,China
- 51 - 100
Details
- Last Funding Type
- Series A
- Industries
- Biopharma,Biotechnology,Pharmaceutical
- Founded date
- Jan 1, 2021
- Number Of Employee
- 51 - 100
- Operating Status
- Active
- Legal Name
- Shize Bio-Pharmaceutical (Shanghai) Co., Ltd.
- Also Known As
- 士泽生物,Shize Biologics,Shize Bio-Pharmaceutical (Shanghai) Co
Xellsmart develops stem cell treatment solutions for a variety of degenerative diseases for which there are now no clinical treatments. Xellsmart is located in Minhang District, Shanghai, China.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
2
¥77M
XellSmart has raised a total of
¥77M
in funding over 2 rounds. Their latest funding was raised on
Sep 7, 2022 from a Series A round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Sep 7, 2022 | Series A | — | 10 |
China Singapore Suzhou Industrial Park Ventures
Eli Lilly
Qiming Venture Partners
|
— | Detail |
| Sep 8, 2021 | Seed | ¥77M | 7 |
Lilly Asia Ventures
Qiming Venture Partners
Sequoia Capital China
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
7
14
XellSmart is funded by 14 investors.
Xiamen Jinyuan Venture Capital
and China Singapore Suzhou Industrial Park Ventures
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
|
Yes | Series A |
|
China Singapore Suzhou Industrial Park Ventures
|
Yes | Series A |
|
Eli Lilly
|
Yes | Series A |
|
Qiming Venture Partners
|
Yes | Series A |
|
Lilly Asia Ventures
|
Yes | Seed |
|
|
— | Series A |
Founder H Fund
|
— | Series A |
FREES FUND
|
— | Series A |
Junsan Capital
|
— | Series A |
Oriza Holdings
|
— | Series A |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
